Insulin Resistance, Metabolic Syndrome, Prediabetes
Conditions
Keywords
obesity, inflammation, diabetes
Brief summary
The purpose of this study is to better understand the link between obesity and diabetes or pre-diabetes.
Detailed description
Obesity is the most common and powerful force for creating insulin resistance and metabolic syndrome, however, the molecular basis of this association is not well understood. In this proposal, three independently funded researchers-Philip Kern, MD a clinical investigator, and Charlotte Peterson, PhD and Robert McGehee, PhD, with significant experience in muscle and adipocyte biology, respectively-will formalize a collaborative effort as a natural extension of previous work and shared interests in the fields of obesity, insulin resistance, and tissue lipid accumulation. Our overall hypothesis is that insulin resistance in humans stems largely from ectopic accumulation of intramyocellular lipid (IMCL) during the development of obesity. Further, we hypothesize that excess IMCL accumulation is dependent on secretory proteins derived from a complex interplay between adipocytes and macrophages in adipose tissue. To test these hypotheses, we will examine the interactions among adipocytes, macrophages, and muscle cells isolated and cultured from subjects that are obese with insulin resistance and impaired glucose tolerance (IGT), and from some with Type 2 Diabetes. This study population has elevated IMCL and is at high risk for obesity complications, but avoids the pathophysiologic complications of glucotoxicity. These subjects will be compared to obese subjects with normal glucose tolerance (NGT). Aim 1 will explore mechanisms that contribute to IMCL and elucidate its role in the development of IGT. Cultured muscle cells will be used to determine whether obese subjects with IGT versus NGT demonstrate intrinsic differences in muscle gene expression and metabolic activity under differing extracellular fatty acid concentrations. Lipid accumulation and oxidation, and insulin-mediated glycogen synthesis and signaling will be assessed. Aim 2 will determine if the IMCL accumulation is dependent on adipose tissue secretory proteins. We will use co-cultures of adipocytes, myoblasts, and adipose stromal vascular cells to examine IMCL and the development of insulin resistance. Aim 3 will determine whether the stromal fraction from IGT subjects promotes IMCL more effectively than that from NGT subjects in co-cultures with muscle cells. We will compare the stromal vascular fractions with regard to monocyte/macrophage accumulation and cytokine expression. Aim 4 will determine if improved glucose tolerance in response to a 10-week treatment with pioglitazone results in decreased IMCL and identify cellular mechanisms involved. Co-culture studies will also be used with muscle and stromal cells, before and after pioglitazone treatment. These experiments will provide mechanistic insight into the link between obesity and muscle function leading to metabolic syndrome.
Interventions
Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
Sponsors
Study design
Eligibility
Inclusion criteria
* 18-65 years of age * BMI 28+ * diabetes, impaired glucose tolerance or normal glucose tolerance
Exclusion criteria
* AST \>2x normal * congestive heart failure * history of coronary artery disease * chronic renal insufficiency (creatinine \> 1.4mg/dl) * use of gemfibrozil, ACE inhibitors, and angiotensin receptor II blockers, or anticoagulants
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Insulin Sensitivity Using FSIGT | Baseline and 10 weeks | The frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin. |
| Effects of Pioglitazone on Changes in BMI | Baseline and 10 weeks | Body Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects |
| Changes in Muscle Lipid After Pioglitazone | At baseline and 10 weeks | Muscle lipid following biopsy using oil red-O staining. |
| Changes in Fat Inflammation Following Pioglitazone | Baseline and 10 weeks | macrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lean Subjects Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate. | 60 |
| Obese Subjects Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. | 10 |
| Total | 70 |
Baseline characteristics
| Characteristic | Obese Subjects | Lean Subjects | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 10 Participants | 60 Participants | 70 Participants |
| Age, Continuous | 57 years STANDARD_DEVIATION 2 | 53 years STANDARD_DEVIATION 6 | 55 years STANDARD_DEVIATION 5 |
| Region of Enrollment United States | 10 participants | 60 participants | 70 participants |
| Sex: Female, Male Female | 7 Participants | 45 Participants | 52 Participants |
| Sex: Female, Male Male | 3 Participants | 15 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 60 | 0 / 10 |
| serious Total, serious adverse events | 0 / 60 | 0 / 10 |
Outcome results
Change in Insulin Sensitivity Using FSIGT
The frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin.
Time frame: Baseline and 10 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese Subjects, Baseline | Change in Insulin Sensitivity Using FSIGT | 1.7 FSIGT units (x10^-4/min/uU/ml) | Standard Deviation 0.53 |
| After Pioiglitazone | Change in Insulin Sensitivity Using FSIGT | 2.4 FSIGT units (x10^-4/min/uU/ml) | Standard Deviation 1.01 |
| Lean Subjects, Baseline | Change in Insulin Sensitivity Using FSIGT | 7.02 FSIGT units (x10^-4/min/uU/ml) | Standard Deviation 3.7 |
Changes in Fat Inflammation Following Pioglitazone
macrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese)
Time frame: Baseline and 10 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese Subjects, Baseline | Changes in Fat Inflammation Following Pioglitazone | 27 macrophages per mm2 by CD68 staining | Standard Deviation 6.3 |
| After Pioiglitazone | Changes in Fat Inflammation Following Pioglitazone | 19 macrophages per mm2 by CD68 staining | Standard Deviation 9.5 |
| Lean Subjects, Baseline | Changes in Fat Inflammation Following Pioglitazone | 17 macrophages per mm2 by CD68 staining | Standard Deviation 6.2 |
Changes in Muscle Lipid After Pioglitazone
Muscle lipid following biopsy using oil red-O staining.
Time frame: At baseline and 10 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese Subjects, Baseline | Changes in Muscle Lipid After Pioglitazone | 7.0 arbitrary units of oil red O staining | Standard Deviation 5.9 |
| After Pioiglitazone | Changes in Muscle Lipid After Pioglitazone | 4.6 arbitrary units of oil red O staining | Standard Deviation 5.9 |
| Lean Subjects, Baseline | Changes in Muscle Lipid After Pioglitazone | 2.7 arbitrary units of oil red O staining | Standard Deviation 0.84 |
Effects of Pioglitazone on Changes in BMI
Body Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects
Time frame: Baseline and 10 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Obese Subjects, Baseline | Effects of Pioglitazone on Changes in BMI | 32.4 kg/m2 | Standard Deviation 3.89 |
| After Pioiglitazone | Effects of Pioglitazone on Changes in BMI | 33.4 kg/m2 | Standard Deviation 4.36 |
| Lean Subjects, Baseline | Effects of Pioglitazone on Changes in BMI | 22.6 kg/m2 | Standard Deviation 1.9 |